| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 25 | 2022 | 2027 | 1.610 |
Why?
|
| alpha-Fetoproteins | 10 | 2020 | 237 | 1.450 |
Why?
|
| Veterans | 35 | 2023 | 1641 | 1.360 |
Why?
|
| Hepatitis C | 13 | 2018 | 524 | 1.170 |
Why?
|
| Liver Neoplasms | 26 | 2022 | 4557 | 1.160 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2023 | 787 | 1.100 |
Why?
|
| Liver Cirrhosis | 16 | 2020 | 941 | 1.080 |
Why?
|
| United States Department of Veterans Affairs | 18 | 2023 | 605 | 0.890 |
Why?
|
| Barrett Esophagus | 10 | 2013 | 569 | 0.780 |
Why?
|
| Subacute Care | 2 | 2018 | 11 | 0.770 |
Why?
|
| Creatinine | 1 | 2021 | 531 | 0.700 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 602 | 0.680 |
Why?
|
| HIV Infections | 12 | 2022 | 2134 | 0.670 |
Why?
|
| Hepatitis C, Chronic | 10 | 2018 | 451 | 0.650 |
Why?
|
| International Classification of Diseases | 6 | 2018 | 83 | 0.630 |
Why?
|
| Hepatitis B, Chronic | 5 | 2022 | 137 | 0.620 |
Why?
|
| Algorithms | 11 | 2020 | 3890 | 0.620 |
Why?
|
| United States | 52 | 2023 | 15433 | 0.610 |
Why?
|
| Gastroesophageal Reflux | 9 | 2013 | 334 | 0.610 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 32 | 0.600 |
Why?
|
| Proton Pump Inhibitors | 5 | 2017 | 249 | 0.570 |
Why?
|
| Histamine H2 Antagonists | 2 | 2017 | 50 | 0.490 |
Why?
|
| Quality Improvement | 4 | 2024 | 851 | 0.460 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2021 | 421 | 0.450 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 348 | 0.430 |
Why?
|
| Middle Aged | 81 | 2022 | 86204 | 0.420 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 622 | 0.420 |
Why?
|
| Cohort Studies | 28 | 2022 | 9244 | 0.410 |
Why?
|
| Serum | 1 | 2011 | 68 | 0.400 |
Why?
|
| Hospitals, Veterans | 5 | 2021 | 397 | 0.400 |
Why?
|
| Hepatitis B | 3 | 2021 | 258 | 0.390 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 1105 | 0.390 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2018 | 363 | 0.380 |
Why?
|
| Colitis, Ulcerative | 5 | 2017 | 268 | 0.380 |
Why?
|
| Alanine Transaminase | 3 | 2018 | 227 | 0.370 |
Why?
|
| Male | 84 | 2024 | 123000 | 0.360 |
Why?
|
| Anti-Ulcer Agents | 2 | 2009 | 101 | 0.350 |
Why?
|
| Colorectal Neoplasms | 5 | 2017 | 3578 | 0.340 |
Why?
|
| Aged | 59 | 2021 | 70117 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 521 | 0.320 |
Why?
|
| Humans | 105 | 2024 | 261506 | 0.320 |
Why?
|
| Hospital Mortality | 5 | 2023 | 1274 | 0.310 |
Why?
|
| Hepatitis B virus | 4 | 2022 | 217 | 0.310 |
Why?
|
| Female | 79 | 2024 | 141928 | 0.310 |
Why?
|
| Veterans Health | 2 | 2021 | 181 | 0.310 |
Why?
|
| Retrospective Studies | 41 | 2023 | 37905 | 0.310 |
Why?
|
| Hospitals | 4 | 2024 | 485 | 0.300 |
Why?
|
| Anus Neoplasms | 3 | 2021 | 411 | 0.300 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 210 | 0.300 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 257 | 0.300 |
Why?
|
| Risk Factors | 29 | 2021 | 17523 | 0.290 |
Why?
|
| Hospitalization | 6 | 2021 | 2083 | 0.290 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 151 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 5437 | 0.290 |
Why?
|
| Crohn Disease | 4 | 2017 | 351 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 383 | 0.270 |
Why?
|
| Population Surveillance | 4 | 2021 | 627 | 0.270 |
Why?
|
| Incidence | 16 | 2022 | 5673 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2009 | 667 | 0.250 |
Why?
|
| Case-Control Studies | 18 | 2021 | 6100 | 0.250 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 2195 | 0.250 |
Why?
|
| Hepacivirus | 3 | 2013 | 397 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 1303 | 0.240 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 14 | 0.240 |
Why?
|
| Risk Assessment | 9 | 2021 | 6869 | 0.240 |
Why?
|
| Age Factors | 8 | 2019 | 5377 | 0.230 |
Why?
|
| Natural Language Processing | 2 | 2016 | 119 | 0.230 |
Why?
|
| Angioedema | 1 | 2023 | 21 | 0.230 |
Why?
|
| Adult | 45 | 2023 | 77950 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 163 | 0.220 |
Why?
|
| Mass Screening | 6 | 2018 | 1509 | 0.220 |
Why?
|
| Logistic Models | 11 | 2018 | 3441 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 1538 | 0.210 |
Why?
|
| HIV | 2 | 2020 | 229 | 0.200 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 235 | 0.200 |
Why?
|
| Esophageal Neoplasms | 5 | 2019 | 3168 | 0.200 |
Why?
|
| Gout | 1 | 2021 | 31 | 0.200 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2021 | 38 | 0.200 |
Why?
|
| Body Mass Index | 3 | 2018 | 2203 | 0.190 |
Why?
|
| Postoperative Complications | 4 | 2024 | 5542 | 0.190 |
Why?
|
| Perioperative Period | 1 | 2021 | 155 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2020 | 2218 | 0.190 |
Why?
|
| Prevalence | 12 | 2021 | 3260 | 0.180 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 29902 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 585 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2022 | 350 | 0.170 |
Why?
|
| Registries | 7 | 2019 | 2170 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 128 | 0.160 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 38 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 598 | 0.160 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 56 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 849 | 0.160 |
Why?
|
| Adipokines | 1 | 2018 | 96 | 0.150 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 551 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2020 | 604 | 0.150 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 187 | 0.150 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 4892 | 0.150 |
Why?
|
| Gastric Acid | 1 | 2017 | 42 | 0.150 |
Why?
|
| Platelet Count | 2 | 2018 | 490 | 0.150 |
Why?
|
| Outpatients | 2 | 2013 | 462 | 0.150 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 6009 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 1054 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 297 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 228 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 1085 | 0.140 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 108 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2021 | 2316 | 0.140 |
Why?
|
| Tuberculin Test | 1 | 2017 | 132 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 3976 | 0.140 |
Why?
|
| Hypertension | 2 | 2023 | 1503 | 0.140 |
Why?
|
| Colonoscopy | 2 | 2012 | 518 | 0.140 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 289 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2017 | 233 | 0.130 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 82 | 0.130 |
Why?
|
| Liver Function Tests | 2 | 2014 | 173 | 0.130 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2013 | 375 | 0.130 |
Why?
|
| Antiviral Agents | 5 | 2022 | 1230 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 135 | 0.130 |
Why?
|
| Prognosis | 10 | 2021 | 21713 | 0.130 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 367 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2017 | 275 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 447 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 552 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 461 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 343 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 164 | 0.120 |
Why?
|
| Databases as Topic | 2 | 2011 | 133 | 0.120 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 53 | 0.120 |
Why?
|
| Medical History Taking | 2 | 2016 | 173 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2017 | 9180 | 0.120 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 4314 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2005 | 82 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 14889 | 0.120 |
Why?
|
| Stomach | 2 | 2007 | 387 | 0.120 |
Why?
|
| Risk Adjustment | 2 | 2021 | 83 | 0.120 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 980 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2017 | 703 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 698 | 0.110 |
Why?
|
| ROC Curve | 2 | 2021 | 1183 | 0.110 |
Why?
|
| Viremia | 2 | 2011 | 177 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2014 | 165 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2020 | 708 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 573 | 0.110 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 4971 | 0.110 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 59 | 0.110 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 43 | 0.110 |
Why?
|
| Data Collection | 4 | 2023 | 620 | 0.110 |
Why?
|
| Fructose | 1 | 2013 | 72 | 0.110 |
Why?
|
| Hepatitis | 1 | 2013 | 93 | 0.110 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 134 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 95 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 1946 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2014 | 273 | 0.110 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 103 | 0.100 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 92 | 0.100 |
Why?
|
| Current Procedural Terminology | 1 | 2011 | 6 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 4988 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 126 | 0.100 |
Why?
|
| Health Services Administration | 1 | 2011 | 13 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 935 | 0.100 |
Why?
|
| Smoking | 3 | 2019 | 2440 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2022 | 32848 | 0.100 |
Why?
|
| Spironolactone | 1 | 2011 | 22 | 0.100 |
Why?
|
| Endoscopy | 2 | 2012 | 479 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2018 | 1863 | 0.100 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.100 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 30 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2008 | 317 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 324 | 0.100 |
Why?
|
| Time Factors | 5 | 2018 | 12926 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 340 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5061 | 0.090 |
Why?
|
| Cause of Death | 3 | 2016 | 752 | 0.090 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 4298 | 0.090 |
Why?
|
| Health Facilities | 1 | 2010 | 79 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2013 | 583 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2010 | 233 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 444 | 0.090 |
Why?
|
| Esophagus | 2 | 2011 | 553 | 0.090 |
Why?
|
| Calibration | 1 | 2010 | 337 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2013 | 649 | 0.090 |
Why?
|
| Managed Care Programs | 1 | 2009 | 74 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 294 | 0.090 |
Why?
|
| Biomarkers | 4 | 2018 | 5047 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Family Health | 1 | 2010 | 325 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2011 | 577 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 233 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 907 | 0.080 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 1258 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 262 | 0.080 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 202 | 0.080 |
Why?
|
| Cardia | 1 | 2007 | 39 | 0.080 |
Why?
|
| Heart Failure | 3 | 2016 | 2516 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2013 | 787 | 0.080 |
Why?
|
| Risk | 3 | 2020 | 1972 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Survival Rate | 5 | 2021 | 12221 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2011 | 636 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2013 | 899 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 2403 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 693 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2278 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 2139 | 0.070 |
Why?
|
| Military Personnel | 1 | 2009 | 225 | 0.070 |
Why?
|
| Electronic Health Records | 4 | 2017 | 929 | 0.070 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 469 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 4320 | 0.070 |
Why?
|
| Comorbidity | 3 | 2020 | 2352 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 509 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 173 | 0.060 |
Why?
|
| Fundoplication | 1 | 2005 | 56 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2005 | 45 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 291 | 0.060 |
Why?
|
| Infliximab | 2 | 2017 | 130 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 1081 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2021 | 12873 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 808 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 7789 | 0.060 |
Why?
|
| Medicare | 3 | 2018 | 860 | 0.060 |
Why?
|
| Adolescent | 9 | 2023 | 31252 | 0.060 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 147 | 0.060 |
Why?
|
| Gulf War | 1 | 2023 | 8 | 0.060 |
Why?
|
| Obesity | 4 | 2022 | 2884 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 589 | 0.060 |
Why?
|
| Patient Selection | 1 | 2010 | 2055 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 397 | 0.050 |
Why?
|
| Age Distribution | 3 | 2013 | 698 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1021 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 23 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 61 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 245 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2003 | 81 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 376 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1225 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 7551 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 6311 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10331 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 395 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2003 | 162 | 0.050 |
Why?
|
| Demography | 2 | 2016 | 435 | 0.050 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 146 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2013 | 756 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 4367 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2005 | 441 | 0.050 |
Why?
|
| Hernia, Hiatal | 2 | 2012 | 63 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5687 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 700 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 666 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 140 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 464 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 44 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 953 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 624 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 13 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 9 | 0.040 |
Why?
|
| Edible Grain | 1 | 2018 | 54 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 130 | 0.040 |
Why?
|
| Anxiety | 1 | 2005 | 1179 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 2315 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 180 | 0.040 |
Why?
|
| Body Weight | 1 | 2022 | 1293 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 218 | 0.040 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 6 | 0.040 |
Why?
|
| Adalimumab | 1 | 2017 | 38 | 0.040 |
Why?
|
| Adiponectin | 1 | 2018 | 163 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 203 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 1000 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2018 | 137 | 0.040 |
Why?
|
| Helicobacter pylori | 2 | 2019 | 1295 | 0.040 |
Why?
|
| Postmenopause | 1 | 2018 | 378 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 295 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 57 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2013 | 1171 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 644 | 0.030 |
Why?
|
| Fruit | 1 | 2018 | 294 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Metaplasia | 2 | 2007 | 383 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 314 | 0.030 |
Why?
|
| Vegetables | 1 | 2018 | 325 | 0.030 |
Why?
|
| Depression | 1 | 2005 | 1715 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2002 | 862 | 0.030 |
Why?
|
| Recurrence | 2 | 2017 | 4758 | 0.030 |
Why?
|
| Pain | 1 | 2003 | 1658 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 170 | 0.030 |
Why?
|
| Esophagitis | 2 | 2006 | 202 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 1099 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 661 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 6682 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 590 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 21 | 0.030 |
Why?
|
| Gastritis | 2 | 2007 | 373 | 0.030 |
Why?
|
| Neoplasms | 1 | 2018 | 15193 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 353 | 0.030 |
Why?
|
| Biopsy | 2 | 2011 | 3443 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1440 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 33 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8865 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 827 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 254 | 0.020 |
Why?
|
| Ribavirin | 1 | 2011 | 178 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 556 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8223 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 259 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 235 | 0.020 |
Why?
|
| Colon | 1 | 2012 | 670 | 0.020 |
Why?
|
| Child | 4 | 2013 | 29154 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 1011 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 671 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 752 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 2007 | 60 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 55 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 40 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 47 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 47 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 2006 | 72 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 52 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 29 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 64 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 74 | 0.020 |
Why?
|
| Prejudice | 1 | 2006 | 57 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 215 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 674 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2006 | 140 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 306 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 200 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 2588 | 0.020 |
Why?
|
| Sleep Deprivation | 1 | 2005 | 51 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2005 | 131 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2004 | 111 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 613 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 13658 | 0.010 |
Why?
|
| Life Style | 1 | 2007 | 612 | 0.010 |
Why?
|
| Infant | 2 | 2011 | 13310 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 1216 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2005 | 295 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 16273 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7702 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2307 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 2522 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 1472 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 285 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1819 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 1239 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3230 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 691 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 1904 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 524 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 4744 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 4532 | 0.010 |
Why?
|